- Home
- ACIU vs AMRN Comparison
ACIU vs AMRN Comparison
Compare ACIU & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | AMRN |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | Switzerland | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 304.7M |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ACIU | AMRN |
|---|---|---|
| Price | $2.24 | $14.12 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 266.5K | 50.3K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $706.75 | N/A |
| Revenue Next Year | $321.13 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $1.65 | $11.67 |
| 52 Week High | $4.00 | $20.90 |
Technical Indicators
Market Signals| Indicator | ACIU | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 24.95 | 44.79 |
| Support Level | $2.03 | $13.46 |
| Resistance Level | $3.92 | $14.49 |
| Average True Range (ATR) | 0.17 | 0.52 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 3.06 | 37.86 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.